Forte Biosciences Company Insiders
| FBRX Stock | USD 0.73 0.01 1.39% |
Forte Biosciences' insiders are aggressively buying. The analysis of the overall insider sentiment regarding Forte Biosciences suggests that vertually all insiders are extremely bullish. Forte Biosciences employs about 9 people. The company is managed by 5 executives with a total tenure of roughly 21 years, averaging almost 4.0 years of service per executive, having 1.8 employees per reported executive.
Forte Biosciences' Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2023-12-18 | Paul A Wagner | Acquired 10000 @ 0.75 | View | ||
| 2023-12-13 | Paul A Wagner | Acquired 10520 @ 0.7 | View | ||
| 2023-12-11 | Paul A Wagner | Acquired 25000 @ 0.65 | View | ||
| 2023-12-07 | Paul A Wagner | Acquired 36203 @ 0.58 | View | ||
| 2023-11-22 | Paul A Wagner | Acquired 400 @ 0.43 | View | ||
| 2023-11-20 | Paul A Wagner | Acquired 6966 @ 0.44 | View |
Monitoring Forte Biosciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Forte |
Forte Biosciences Management Team Effectiveness
The company has return on total asset (ROA) of (0.5015) % which means that it has lost $0.5015 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8492) %, meaning that it created substantial loss on money invested by shareholders. Forte Biosciences' management efficiency ratios could be used to measure how well Forte Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.85 in 2024. Return On Capital Employed is likely to rise to -0.87 in 2024. At this time, Forte Biosciences' Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 831.9 K in 2024, whereas Non Current Assets Total are likely to drop slightly above 620.3 K in 2024.Common Stock Shares Outstanding is likely to rise to about 33.1 M in 2024, whereas Net Loss is likely to drop (16.8 M) in 2024.
Forte Biosciences Workforce Comparison
Forte Biosciences is rated below average in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 768. Forte Biosciences claims roughly 9.0 in number of employees contributing just under 2% to equities under Health Care industry.
Forte Biosciences Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Forte Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Forte Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Forte Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Riley Antony A few days ago Disposition of 9375 shares by Riley Antony A of Forte Biosciences subject to Rule 16b-3 | ||
Paul Wagner over two weeks ago Acquisition by Paul Wagner of 100 shares of Forte Biosciences at 0.4251 subject to Rule 16b-3 | ||
Paul Wagner over three weeks ago Disposition of 31250 shares by Paul Wagner of Forte Biosciences subject to Rule 16b-3 | ||
Paul Wagner over a month ago Acquisition by Paul Wagner of 1100000 shares of Forte Biosciences at 0.69 subject to Rule 16b-3 | ||
Paul Wagner over a month ago Disposition of 4109 shares by Paul Wagner of Forte Biosciences at 0.8217 subject to Rule 16b-3 | ||
Riley Antony A over three months ago Exercise or conversion by Riley Antony A of 9375 shares of Forte Biosciences subject to Rule 16b-3 | ||
Paul Wagner over three months ago Purchase by Paul Wagner of 10000 shares of Forte Biosciences | ||
Paul Wagner over three months ago Purchase by Paul Wagner of 25000 shares of Forte Biosciences |
Forte Biosciences Notable Stakeholders
A Forte Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Forte Biosciences often face trade-offs trying to please all of them. Forte Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Forte Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Paul Wagner | President CEO | Profile | |
| Hubert MD | President Officer | Profile | |
| Antony CPA | Chief Officer | Profile | |
| Steven Ruhl | Chief Officer | Profile | |
| Christopher Roenfeldt | Chief Officer | Profile |
About Forte Biosciences Management Performance
The success or failure of an entity such as Forte Biosciences often depends on how effective the management is. Forte Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Forte management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Forte management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.81) | (0.85) | |
| Return On Capital Employed | (0.92) | (0.87) | |
| Return On Assets | (0.81) | (0.85) | |
| Return On Equity | (0.89) | (0.94) |
The data published in Forte Biosciences' official financial statements usually reflect Forte Biosciences' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Forte Biosciences. For example, before you start analyzing numbers published by Forte accountants, it's critical to develop an understanding of what Forte Biosciences' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Forte Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Forte Biosciences' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Forte Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Forte Biosciences. Please utilize our Beneish M Score to check the likelihood of Forte Biosciences' management manipulating its earnings.
Forte Biosciences Workforce Analysis
Traditionally, organizations such as Forte Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Forte Biosciences within its industry.Forte Biosciences Manpower Efficiency
Return on Forte Biosciences Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 3.5M | |
| Net Loss Per Executive | 6.3M | |
| Working Capital Per Employee | 3.9M | |
| Working Capital Per Executive | 6.9M |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Forte Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Forte Stock please use our How to Invest in Forte Biosciences guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Complementary Tools for Forte Stock analysis
When running Forte Biosciences' price analysis, check to measure Forte Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Forte Biosciences is operating at the current time. Most of Forte Biosciences' value examination focuses on studying past and present price action to predict the probability of Forte Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Forte Biosciences' price. Additionally, you may evaluate how the addition of Forte Biosciences to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Transaction History View history of all your transactions and understand their impact on performance |
Is Forte Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Forte Biosciences. If investors know Forte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Forte Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.00) | Return On Assets (0.50) | Return On Equity (0.85) |
The market value of Forte Biosciences is measured differently than its book value, which is the value of Forte that is recorded on the company's balance sheet. Investors also form their own opinion of Forte Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Forte Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Forte Biosciences' market value can be influenced by many factors that don't directly affect Forte Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Forte Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Forte Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Forte Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.